Erythromycin Ethylsuccinate (E-Mycin E)

Subscribe to Selected New Research on Erythromycin Ethylsuccinate

130 relevant articles (12 outcomes, 21 trials/studies) found for this Drug

Description: A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Also Known As:

E-Mycin E; EryPed; Erythroped; Eyrthromycin Ethyl Succinate; Pediamycin; Wyamycin E; EMycin E; Ethyl Succinate, Eyrthromycin; Ethylsuccinate, Erythromycin; Succinate, Eyrthromycin Ethyl; Monomycin; Erythromycin, 2'-(ethyl butanedioate)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Lactones: 134

Macrolides: 754

Erythromycin: 2914

Erythromycin Ethylsuccinate: 130

Polycyclic Compounds: 58

Macrocyclic Compounds: 1

Macrolides: 754

Erythromycin: 2914

Erythromycin Ethylsuccinate: 130

Erythromycin Ethylsuccinate: 130

Related Diseases

1.	Impetigo 05/01/1990 - "The results of the trial indicate that 2% mupirocin ointment is as safe and effective as oral erythromycin ethylsuccinate in the treatment of patients with impetigo." 12/01/1988 - "The safety and efficacy of a new topical antiinfective agent, mupirocin, was compared with that of oral erythromycin ethylsuccinate in the treatment of impetigo in children" 08/01/1989 - "In this study, a new topical antibiotic ointment, mupirocin, was compared with oral erythromycin ethylsuccinate in the treatment of impetigo" 05/01/1990 - "Sixty patients participated in a bacteriologically controlled, randomized, parallel group comparison of 2% mupirocin ointment (Bactroban) and oral erythromycin ethylsuccinate for the treatment of impetigo" 11/01/1988 - "Results from this study demonstrate that mupirocin is as effective as systemic erythromycin ethylsuccinate for treatment of pyoderma and impetigo." Order ALL the reference details at left...
2.	Respiratory Tract Infections (Respiratory Tract Infection) 09/01/1989 - "Erythromycin ethylsuccinate, base and acistrate in the treatment of upper respiratory tract infection: two comparative studies of tolerability." 01/01/1979 - "With its good absorption, its lack of toxicity and its reputation for good diffusion into bronchial secretions, we consider that erythromycin ethylsuccinate should have a major place in the treatment of respiratory tract infections." 03/01/1993 - "In the present double-blind, placebo-controlled trial, the effect of erythromycin ethylsuccinate (0.5 g twice a day for 5 days) on the elimination of nasopharyngeal pathogens and reduction of clinical signs of upper respiratory tract infection, as well as on subjective complaints, was evaluated in 106 adults with acute laryngitis" 10/01/1990 - "This study indicates that both erythromycin ethylsuccinate and ciprofloxacin are well tolerated and are equally effective for routine empirical treatment of acute respiratory tract infections." 10/01/1990 - "Comparison of oral erythromycin ethylsuccinate and ciprofloxacin in the treatment of acute respiratory tract infections." Order ALL the reference details at left...
3.	Otitis Media 10/01/1986 - "In the first phase, erythromycin ethylsuccinate was used as prophylaxis for otitis media in 45 patients in a dose of 10 mg/kg twice daily" 05/01/1994 - "These included withholding antimicrobials for treatment of the preceding episode of otitis media; use of suboptimal agents for therapy of otitis media (penicillin and, possibly, erythromycin ethylsuccinate); and insufficient duration of treatment." 12/01/1978 - "Ninety young children with otitis media, proven by tympanocentesis culture to be due to Hemophilus influenzae, were treated in a prospective double-blind study with one of three antimicrobial regimens: ampicillin, erythromycin ethylsuccinate, or erythromycin ethylsuccinate with concomitant trisulfapyrimidines" 01/01/1983 - "The erythromycin ethylsuccinate and acetyl sulfisoxazole combination was effective in treatment of acute otitis media secondary to ampicillin-resistant Haemophilus influenzae" 05/01/1988 - "Erythromycin ethylsuccinate-sulfamethoxazole mixture vs. amoxicillin for acute otitis media." Order ALL the reference details at left...
4.	Pharyngitis (Sore Throat) 10/01/1988 - "Roxithromycin and erythromycin ethylsuccinate were equally effective in resolving the symptoms and signs of pharyngitis" 11/01/1982 - "Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate." 10/01/1988 - "We compared the efficacy and toxicity of roxithromycin and erythromycin ethylsuccinate in the treatment of streptococcal pharyngitis in adults" 10/01/1988 - "Comparative efficacy and toxicity of roxithromycin and erythromycin ethylsuccinate in the treatment of streptococcal pharyngitis in adults." 01/01/1988 - "Two hundred sixty-five adult and adolescent patients with possible streptococcal pharyngitis were treated with either erythromycin ethylsuccinate or an enteric-coated erythromycin in a twice-daily dosage schedule" Order ALL the reference details at left...
5.	Dysentery 07/01/1979 - "It was concluded that an excessive protein content in the diet increased the efficacy of monomycin therapy in dysentery children" 07/01/1979 - "It is recommended that the diet with an excessive protein content be used in monomycin treatment of dysentery children." 07/01/1979 - "Course of dysentery and the specific alteration of the neutrophils in children in the use of monomycin and a diet with an increased protein content]" 07/01/1978 - "Wide use of eleuterococcus in combination with monomycin for the treatment of children with dysentery is recommended." 07/01/1978 - "An acute dysentery process was studied in 100 children at the age of 1 to 14 years treated with monomycin; 54 patients (the 1st group) were treated with monomycin in combination with eleuterococcus and 46 patients (the 2nd group) were treated with monomycin alone" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Mupirocin (Bactroban)
2.	Anti-Bacterial Agents (Antibiotics)
3.	Amoxicillin (Wymox)
4.	Ciprofloxacin (Cipro)
5.	Ampicillin (Omnipen)
6.	Roxithromycin
7.	Sulfisoxazole (Sulfafurazole)
8.	Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)
9.	Clavulanic Acid (Potassium Clavulanate)
10.	ekmolin

Related Therapies and Procedures

1.	Tonsillectomy
2.	Sutures (Suture)
3.	Middle Ear Ventilation (Tympanostomy)
4.	Aftercare (After-Treatment)
5.	Adenoidectomy

Best Treatments:
Research Summary Report
on Impetigo

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 31 Outcomes
Top 163 Key Drugs and Biologics
Top 11 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>